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Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic dis-
eases that may modify body composition. Adipose tissue has the ability to release a
wide range of products involved in physiologic functions, but also in various pathological
processes, including the inflammatory/immune response. RA and AS are both associated
with the development of cardiovascular complications. It is has been established that
central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked
to cardiovascular events.Thus, in this study, we aimed to evaluate the body composition of
patients with RA or AS compared to healthy controls (HC), with a special emphasis on the
visceral region. In parallel, we measured adipose products or adipokines, namely leptin,
adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric
peptide that plays a role in energetic balance. The homeostasis model assessment for
insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular
risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS,
and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to
determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions,
and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary,
adiposity was increased in RA (p=0.01) while visceral fat was also increased, but only in
women (p=0.01). Patients with AS tended to have lower total fat mass (p=0.07) and
higher lean mass compared to HC (p= 0.07). Leptin and leptin/fat mass were decreased
in male patients with AS (p<0.01), while total adiponectin and the ratio of HMW to total
adiponectin were both increased in RA (p<0.01).There were no changes in serum resistin
and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modi-
fied in RA and AS. These results confirm that body composition was altered in RA and AS,
affecting distinct soft tissue compartments. The effect of the increased visceral adipose
tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic
profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index.
Keywords: fat mass, body composition, visceral fat, leptin, adiponectin, cardiovascular risk
INTRODUCTION
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are
inflammatory joint diseases that are characterized by peripheral
symmetrical polysynovitis and axial skeleton involvement, respec-
tively. They are both associated with changes in body composition.
Indeed, loss of skeletal muscle mass and accumulation of body fat
are observed in patients with RA and this phenomenon is known
as rheumatoid cachexia (1). In AS, a predominant loss of appen-
dicular lean mass is described, while body fat remains unaltered (2,
3). Cachexia can be defined as a loss of skeletal muscle or lean mass
and is associated with decreased muscle function, weakness and
physical inactivity, and thus may strongly contribute to the disabil-
ity that complicates these diseases (1). It is now well established
that pro-inflammatory cytokines, such as TNF-α, play a major role
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in driving inflammation in RA and AS. Together with the disease
activity, it is believed that such pro-inflammatory cytokines are
linked to the development of body composition alterations in RA
and AS (4).
It is now well recognized that RA and AS are associated with
accelerated atherosclerosis, and thus, with increased cardiovas-
cular morbidity and mortality (5). Body composition may be
evaluated using dual-energy X-ray absorptiometry (DXA) and
measurements include total lean and fat mass, but specific anatom-
ical regions may also be investigated. In fact, when evaluating
cardiovascular risk in patients with chronic inflammatory condi-
tions,android fat deposits in the abdominal region are of particular
interest (6, 7). Fat accumulation in the android region refers to
abdominal fat that can be subclassified into subcutaneous and vis-
ceral fat (8). It has previously been demonstrated that visceral fat,
rather than subcutaneous fat, is a major predictor of adverse car-
diovascular events (9). Therefore, the assessment of android or
visceral fat in chronic inflammatory rheumatic diseases, such as
RA and AS, is a relevant issue.
In parallel, it is established that adipose tissue is not only a
storage organ, but is able to produce a wide variety of factors
called adipokines, such as leptin, adiponectin, resistin, and vis-
fatin (10). These bioactive substances are involved in physiologic
functions and could participate in various pathological processes,
including inflammation and immunity (10–12). They also con-
tribute to the pathophysiology of obesity and/or immune-related
diseases, such as RA or AS (13). Leptin, the first adipokine to
be described, is involved in appetite regulation and promotes
pro-inflammatory responses (12). Adiponectin plays a central
metabolic role by its insulin sensitivity and anti-atherogenic prop-
erties (14). On the other hand, the influence of adiponectin on
immune response is still controversial, with the description of
both pro- and anti-inflammatory effects (12, 15). Different mole-
cular forms of adiponectin are described, with opposite effects on
inflammatory processes, with the high molecular weight (HMW)
form driving pro-inflammatory effects, while the low molecu-
lar form displays anti-inflammatory properties (16). Resistin is
another adipokine considered to have pro-inflammatory effects
(11, 12). In addition to these adipose-derived substances, ghrelin
is a gastric peptide that stimulates food intake. In parallel, ghrelin
has anti-inflammatory activities, especially in inflammatory joint
conditions (17).
The assessment of adipose tissue and the substances it secretes
is therefore of prime concern in RA and AS. Circulating adipokine
levels have been widely evaluated in RA, and to a lesser extent in
AS, showing elevated serum concentrations, suggesting that these
adipose products contribute to the inflammatory response (11,
12). A limited number of studies have evaluated body compo-
sition in RA and AS, without specific assessment of fat distri-
bution in the android or visceral regions (18). Since both RA
and AS are associated with increased cardiovascular risk, and
display changes in body composition measurements as well as
altered circulating adipokine levels, we aimed to evaluate adipose
tissue and its distribution in this study, with a special empha-
sis on the android and visceral regions, and to measure serum
adipokines and ghrelin. Therefore, body composition measure-
ments and adipokines that are linked to cardiovascular events, as
well as cardiometabolic parameters such as insulin sensitivity were
specifically evaluated.
PATIENTS AND METHODS
PATIENTS
This was a single-center, cross-sectional study. Consecutive inpa-
tients or outpatients with RA or AS treated in the department
of Rheumatology of the University Hospital of Besançon were
included. Two physicians (ET, DW) recruited patients during
scheduled consultations or hospitalizations. Patients with RA who
fulfilled the 1987 American College of Rheumatology criteria (19)
and patients with AS who met the modified New York criteria
(20) were included. In the RA group, patients were receiving
traditional disease-modifying anti-rheumatic drugs (DMARDs)
[methotrexate, leflunomide, sulfasalazine (SLZ), or hydroxy-
chloroquine] and/or low dose corticosteroids (CTC) (≤10 mg
prednisone daily). In the AS group, patients were receiving non-
steroidal anti-inflammatory drugs (NSAIDs) and/or SLZ. No
patient was receiving, or had previously received a biologic agent
(anti-TNF-α, abatacept, tocilizumab, rituximab, or anakinra). We
excluded patients with diabetes mellitus and other endocrine dis-
orders, as well as patients receiving high dose CTC (>10 mg
prednisone daily). No patient in this study had lipid lowering
drugs.
HEALTHY CONTROLS
The control group consisted of healthy subjects recruited among
the hospital staff, without inflammatory conditions or treatment
(including CTC and lipid lowering drugs). Exclusion criteria were
the same as for the patient group, i.e., subjects with diabetes and
endocrine disorders were excluded.
All patients and healthy control (HC) gave written informed
consent. The study protocol was performed in accordance with the
Helsinki declaration and approved by the local ethics committee
(Comité d’Éthique Clinique du CHU de Besançon).
METHODS
Clinical data
Clinical characteristics were recorded in each patient group.
In the RA group, disease activity and functional impairment
were evaluated using the Disease Activity Score (DAS28) and
the Health Assessment Questionnaire (HAQ), respectively. For
patients with AS, clinical activity was evaluated using the Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI) and the
Bath Ankylosing Spondylitis Functional Index (BASFI). Weight
and body mass index (BMI) were evaluated. According to their
BMI, patients were defined as underweight (BMI <18.5 kg/m2),
normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), or
obese (≥30 kg/m2).
Inflammatory and immunological parameters
Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP),
and IL-6 serum levels [IL-6 enzyme-linked immunosorbent assay
(ELISA) kit II BD OptEIA, BD Biosciences, Le Pont de Claix,
France] were used to assess inflammation. Positivity for rheuma-
toid factors, anti-CCP antibodies and HLA-B27 status was also
recorded.
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Adipokines, ghrelin, and cardiometabolic parameters
After overnight fasting, venous blood samples were collected
and centrifuged (for 10 min at 1500 g ) as soon as possible.
Serum aliquots were stored at −80°C until biochemistry assays.
Total adiponectin, total ghrelin and leptin were determined by
radioimmunoassay (RIA) (Millipore, St Charles, MO, USA for
total adiponectin and ghrelin and Mediagnost GmbH, Reutlin-
gen, Germany for leptin). The inter-assay coefficients of varia-
tion (CV) were 6.9, 7.9, and 7.6% for total adiponectin, ghre-
lin, and leptin, respectively. Resistin (R&D systems Europe Ltd.,
Lille, France) and HMW adiponectin (Millipore, St Charles, MO,
USA) were measured by quantitative sandwich ELISA and inter-
assay CVs were 7.7 and 7.8%, respectively. The ratio of HMW
to total adiponectin was calculated. The lowest level that could
be detected by each assay (sensitivity) was 0.5 ng/mL for leptin,
1µg/mL for total adiponectin, 0.5µg/mL for HMW adiponectin,
0.02 ng/mL for resistin, and 93 pg/mL for ghrelin. Glucose levels
were assessed on Dimension RXL, using hexokinase-glucose-6-
phosphate dehydrogenase method (Siemens Healthcare Diagnos-
tics Ltd., Camberley, UK) with an inter-assay CV of 1.4%. Insulin
was measured by an enzyme immunoassay, with an inter-assay
CV of 4.6%, on an AIA 1800 (Tosoh Bioscience, Tessenderlo,
Belgium). The homeostasis model assessment for insulin resis-
tance (HOMA-IR), calculated as fasting insulin (mU/L)× fasting
glucose (mmol/L)/22.5, was used to estimate insulin resistance
(21). Since leptin levels are strongly associated with the amount
of adipose tissue (10), we determined leptin corrected for fat
mass. In addition, it is known that women have higher serum
leptin compared to men (10) and a similar but more limited
gender effect is also reported for adiponectin. Thus, results for
leptin and adiponectin were given separately for men and women.
The influence of gender on the production of other adipokines
is not clearly determined and thus, resistin and ghrelin results
were also given according to gender. Fasting serum total choles-
terol, as well as low density lipoprotein (LDL) and high density
lipoprotein (HDL) cholesterol were also evaluated. The athero-
genic index, defined as the ratio of total/HDL cholesterol, was
calculated.
Assessment of adipose tissue
A total body scan was performed using a Lunar iDXA densitometer
(GE Healthcare, Madison, WI, USA). Quality control scans were
performed daily during the study period. Subjects were scanned
using standard imaging and positioning protocols according to
the manufacturer’s instructions. Body composition was studied
from the total body scan, with measurements of fat mass and lean
mass. Total and regional body fat mass and lean mass were also
determined. Adiposity (% fat) was defined as the ratio of total fat
tissue to (total lean mass+ total fat tissue). Fat distribution was
evaluated as the relative proportion of fat tissue in the android
(abdominal) and gynoid (hip and thigh) regions. For the mea-
surement of android fat, a region of interest was automatically
defined (from the top of the iliac crest to 20% of the distance
from the top of the iliac crest to the base of the skull). Visceral
adipose tissue was calculated using Lunar CoreScan software (GE
Healthcare, Madison, WI, USA), which estimates specific intra-
abdominal adipose tissue, excluding subcutaneous abdominal fat
(8). The CV for adiposity, fat mass, and lean mass were 0.63, 0.59,
and 0.45%, respectively (22).
STATISTICAL ANALYSIS
Results are expressed as mean± standard error of the mean (SEM).
Due to a lack of normal distribution of the assessed variables, non-
parametric tests were used. Statistical analysis between the three
groups (RA, AS, and HC) involved non-parametric analysis of
variance (ANOVA) using the Kruskal–Wallis test. This test was
used to compare age, BMI, ESR, CRP, and IL-6, serum adipokine
(serum leptin, leptin/fat mass, total and HMW adiponectin,
HMW/total adiponectin ratio, resistin) and ghrelin levels, car-
diometabolic parameters (fasting glycemia, insulin, HOMA-IR,
total cholesterol, LDL and HDL cholesterol, total/HDL choles-
terol), and body composition measurements (total fat and lean
masses, adiposity, android and gynoid fat, visceral fat) between
the three groups. When analysis between the three studied groups
was significant, pairwise tests were performed (RA vs. HC or AS vs.
HC) using the Mann–Whitney test. Qualitative data (gender) were
analyzed using the Chi-square test. Spearman’s r was used to cal-
culate correlations between markers of disease activity (ESR, CRP,
IL-6, and DAS28 or BASDAI) and serum adipokine and ghrelin
levels or body composition measurements. A p value< 0.05 was
considered statistically significant for all tests. All analyses were
performed using SigmaStat software (SSS Inc., Chicago, IL, USA).
RESULTS
CLINICAL CHARACTERISTICS OF THE STUDY POPULATION
The demographic and clinical characteristics of the patients and
HC are shown in Table 1. A total of 112 subjects (30 patients with
RA, 31 with AS, and 51 HC) were included over a 1-year period. In
RA, most of the patients had traditional DMARDs and CTC (mean
dose: 5.9± 2.8 mg daily). In patients with AS, treatments given
were NSAIDs and only a limited number had SLZ or CTC (mean
dose: 8.4± 2.8 mg daily). All patients with RA had active disease
(as defined by a DAS28≥ 3.2), as had patients with AS (defined as
a BASDAI≥ 4). Patients with RA were older compared to patients
with AS or HC (Kruskal–Wallis test: p= 0.0002; Mann–Whitney
test RA vs. HC: p= 0.0005; mean difference around 10 years, range
37 to 73 in RA and 26 to 71 in HC). As expected, most enrolled
patients with AS were men (93%) (Chi-square test RA vs. AS vs. HC
p< 0.0001; Chi-square test AS vs. HC: p= 0.007). ESR, CRP, and
IL-6 levels were elevated in RA and AS compared to HC (Kruskal–
Wallis tests: all p< 0.0001; Mann–Whitney tests RA vs. HC and
AS vs. HC, all p< 0.005).
Serum adipokine levels and cardiometabolic parameters
No significant differences were observed between groups for fast-
ing glycemia, HOMA-IR, LDL cholesterol, total/HDL cholesterol,
resistin, and ghrelin levels (Table 2). Insulin levels differed signif-
icantly between the three groups (Kruskall Wallis test p= 0.01)
and this difference was related to lower levels in the AS group
(Mann–Whitney test AS vs. HC: p= 0.009). Total cholesterol and
HDL cholesterol also differed significantly (Kruskal–Wallis tests
p= 0.0008 for both) due to increased HDL levels in the RA group
(Mann–Whitney test RA vs. HC: p= 0.005) and decreased total
cholesterol and HDL levels in the AS group (Mann–Whitney
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Table 1 | Clinical and demographic characteristics of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and healthy controls
(HC).
RA AS HC p* p***
N 30 31 51
Age (years) (range) 56.9±1.8 (37–73) 43.8±2.4 (20–65) 46.6±1.5 (26–71) 0.0002 RA vs. HC: p=0.0005
AS vs. HC p=NS
Sex (M/F) 11/19 28/3 29/22 **<0.0001 **RA vs. HC p=NS
**AS vs. HC p=0.007
Body mass index (kg/m2) M+F 25.5±0.8 24.1±0.6 24.9±0.7 NS
Body mass index (kg/m2) M 25.7±1.2 24.3±0.7 24.8±0.6 NS
Body mass index (kg/m2) F 25.3±1 22±1.3 25±1.3 NS
Underweight (N ) 1 1 1
Normal weight (N ) 14 19 27
Overweight (N ) 10 9 19
Obese (N ) 5 2 4
Disease duration (years) 11.7±1.6 13.1±1.9
Treatments MTX N =23 NSAIDs N =23
LFM N =4 SLZ N =4
SLZ N =2 CTC N =3
CTC N =26
Rheumatoid factors (%) 83.3
Anti CPP (%) 56.6
HLA-B27 (%) 83.4
DAS28 3.5±0.2
HAQ 1.1±0.1
BASDAI 4.4±0.3
BASFI 4.1±0.5
ESR (mm/h) 21.8±3.1 28.5±4.3 12±3.2 <0.0001 RA vs. HC p<0.0001
AS vs. HC p=0.0002
CRP (mg/L) 12.8±2.8 29.5±6.1 4.4±1.1 <0.0001 RA vs. HC p<0.0001
AS vs. HC p<0.001
IL-6 (pg/mL) 34.1±12.3 19.4±3.4 14.4±7.7 <0.0001 RA vs. HC p<0.0001
AS vs. HC p<0.0001
(M, male; F, female; DAS28, disease activity score 28 joints; HAQ, health assessment questionnaire; BASDAI, Bath ankylosing spondylitis disease activity index;
BASFI, Bath ankylosing spondylitis functional index; MTX, methotrexate; LFM, leflunomide; SLZ, sulfasalazine; HCQ, hydroxychloroquine; CTC, corticosteroids; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein; results were given as mean±SEM; *Kruskal–Wallis test; **Chi-square test; ***Mann–Whitney test).
tests p= 0.002 and 0.05, respectively). However, the atherogenic
index of total/HDL cholesterol was found to be similar between
the three groups. The three groups differed in terms of serum
leptin levels (Kruskal–Wallis test p< 0.0001), but this difference
reflected the gender distribution (as stated above, there was a
high proportion of men in the AS group). Thus, leptin results
were analyzed in men and women separately. No difference in
serum leptin and leptin/fat mass ratio was found between the
three groups of women. Conversely, leptin and leptin/fat mass
differed significantly between groups in men (Kruskal–Wallis test
p= 0.03 and 0.01, respectively). Pairwise tests showed that lep-
tin and leptin/fat mass were significantly decreased in male AS
patients (Mann–Whitney tests AS vs. HC p= 0.009 and 0.003,
respectively), while the levels of leptin and the leptin/fat mass ratio
were comparable between male subjects with RA and HC. Total
adiponectin and the ratio of HMW/total adiponectin differed
significantly between groups (Kruskal–Wallis tests p= 0.02 and
p< 0.0001, respectively). These differences were driven by higher
total adiponectin levels in RA compared to HC (Mann–Whitney
tests RA vs. HC for total adiponectin and total/HMW adiponectin:
p= 0.008 and p< 0.0001, respectively). HMW adiponectin also
tended to be higher in patients with RA, but without reaching
the significance level (Kruskal–Wallis test p= 0.09). Finally, we
also examined whether there was a gender effect for resistin and
ghrelin. However, no significant difference was observed in serum
resistin and ghrelin levels when men and women were analyzed
separately (Kruskal–Wallis test, all p> 0.05).
Adipose tissue distribution
Patients and HC did not differ regarding their BMI (in the whole
group, or analyzed separately in men and women) (Kruskal–
Wallis tests, all p> 0.05). The distribution of underweight, normal
weight, overweight, and obese subjects in the three groups is shown
in Table 1. Since the proportion of male patients was higher in the
AS group, the distribution of adipose tissue was examined accord-
ing to gender. Results are given first for the whole group, and then,
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Table 2 | Metabolic parameters, serum ghrelin and adipokine levels of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and
healthy controls (HC) (M, male; F, female; *Kruskal–Wallis test; **Mann–Whitney test).
RA N =30 AS N =31 HC N =51 p* p**
Glycemia (mmol/L) 5±0.1 4.9±0.1 4.6±0.1 NS
Insulin (µIU/L) 8.4±0.9 5.6±0.5 10.7±1.6 0.01 RA vs. HC p=NS
AS vs. HC p=0.009
HOMA-IR 1.9±0.3 1.2±0.1 2.4±0.4 NS
Total cholesterol (g/L) 2.2±0.1 1.8±0.5 2.1±0.1 0.0008 RA vs. HC p=NS
AS vs. HC p=0.002
LDL cholesterol (g/L) 1.2±0.1 1.1±0.1 1.2±0.1 NS
HDL cholesterol (g/L) 0.6±0.1 0.49±0.05 0.5±0.1 0.0008 RA vs. HC p=0.005
AS vs. HC p=0.05
Total/HDL Cholesterol 3.6±0.2 3.8±0.2 3.9±0.2 NS
Leptin (ng/mL) M+F 15.3±2.4 3.5±0.6 14.3±2.3 <0.0001 RA vs. HC p=NS
AS vs. HC p<0.0001
Leptin M (ng/mL) 7.5±3.5 2.8±0.5 5.1±0.7 0.03 RA vs. HC p=NS
AS vs. HC: p=0.009
Leptin F (ng/mL) 19.8±2.7 9.1±1.5 25.2±4.2 NS
Leptin/fat mass (ng/mL/g) M+F 0.54±0.06 0.16±0.02 0.53±0.07 <0.0001 RA vs. HC p=NS
AS vs. HC p<0.0001
Leptin fat mass M (ng/mL/g) 0.24±0.07 0.13±0.01 0.26±0.05 0.01 RA vs. HC p=NS
AS vs. HC: p=0.003
Leptin/fat mass F (ng/mL/g) 0.72±0.06 0.41±0.06 0.87±0.12 NS
Total adiponectin M+F (µg/mL) 13.2±1.1 9.9±0.9 9.4±0.5 0.02 RA vs. HC p=0.008
AS vs. HC p=NS
Total adiponectin M (µg/mL) 12.1±1.1 8.8±0.7 7.9±0.7 0.01 RA vs. HC p=0.003
AS vs. HC NS
Total adiponectin F (µg/mL) 13.8±1.7 20±3.5 11.4±0.6 NS
HMW adiponectin M+F (µg/mL) 9.4±0.9 7.2±0.8 7.6±0.5 0.09
HMW adiponectin M (µg/mL) 8.4±1.1 6.2±0.6 6.2±0.6 NS
HMW adiponectin F (µg/mL) 10±1.3 16.3±3.9 9.6±0.5 NS
HMW/total adiponectin M+F 69.8±1.7 70.4±2 80.4±1.5 <0.0001 RA vs. HC p<0.0001
AS vs. HC NS
HMW/total adiponectin M 68.1±3 69.4±1.9 79.6±2.2 0.002 RA vs. HC p=0.01
AS vs. HC p=0.002
HMW/total adiponectin F 70.8±2 79.5±8.8 81.5±1.9 0.005 RA vs. HC p=0.0008
AS vs. HC NS
Resistin M+F (ng/mL) 11.4±1.1 13.5±1.1 10.6±0.7 NS
Resistin M (ng/mL) 12.4±2.1 13.7±1.2 11.7±0.9 NS
Resistin F (ng/mL) 10.7±1.3 11.4±1.5 9.2±0.8 NS
Ghrelin M+F (pg/mL) 1220.2±75.8 1272.6±70.3 1091.9±43.9 NS
Ghrelin M (pg/mL) 1091.5±106.7 1248±75.1 1035.7±50.8 0.065
Ghrelin F (pg/mL) 1294.6±100.5 1502.7±156 1166.1±75.4 NS
for men and women separately. Total fat mass was significantly
different between the three groups (Kruskal–Wallis test p= 0.01);
there was no significant difference in pairwise testing between RA
and HC, while there was a tendency toward decreased fat mass
in AS (Mann–Whitney test p= 0.07) (Table 3). When examin-
ing total fat mass in men or in women separately, no significant
difference was found between the three groups. Similar results
were obtained for lean mass: total lean mass significantly differed
between the three groups overall (Kruskal–Wallis test p= 0.004),
explained by a tendency toward higher lean mass in the AS group
(Mann–Whitney test AS vs. HC p= 0.07), but again, no difference
was found between the three groups when men and women were
analyzed separately. The three groups also differed overall regard-
ing adiposity (Kruskal–Wallis test p= 0.0001) and this difference
was explained by higher values in RA (Mann–Whitney test RA vs.
HC p= 0.01) while lower values were observed in AS (Mann–
Whitney test AS vs. HC p= 0.01). However, these differences
did not persist when men and women were analyzed separately.
Android fat was similar between the three groups although there
was a tendency toward decreased fat mass in the AS group, without
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Table 3 | Body composition measurements of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and healthy controls (HC) (M,
male; F, female; *Kruskal–Wallis test; **Mann–Whitney test).
RA N =30 AS N =31 HC N =51 p* p**
Total fat mass M+F (g) 24997.8±1645.5 18516.8±1773.4 21639.5±1357.6 0.01 RA vs. HC p=NS
AS vs. HC p=0.07
Total fat mass M (g) 22524±3414.1 18195.8±1955 20014.5±1552.4 NS
Total fat mass F (g) 26430±1681.7 21513±854.5 23728.8±2341.8 NS
Total lean mass M+F (g) 42270.9±1520.7 49839.3±1251.2 46073.3±1444.2 0.004 RA vs. HC p=NS
AS vs. HC p=0.07
Total lean mass M (g) 50665.7±1280.7 51330.8±1022.6 52967.2±1431.1 NS
Total lean mass F (g) 37410.7±1332.7 35918±1896.2 37209.7±893 NS
Adiposity (%) M+F 36.7±1.6 25.9±1.6 31.9±1.3 0.0001 RA vs. HC p=0.01
AS vs. HC p=0.01
Adiposity M (%) 29.4±2.9 24.7±1.6 26.5±1.3 NS
Adiposity F (%) 40.9±1.1 37.5±1.8 38.8±1.6 NS
Android fat M+F (g) 2465.6±226.1 1811.8±236.6 2293.1±223.8 0.055 RA vs. HC p=NS
AS vs. HC p=NS
Android fat M (g) 2448.4±492.6 1384.5±261.6 2469.4±356.7 NS
Android fat F (g) 2475.6±227.9 1607.7±163.2 2066.4±227.7 NS
Gynoid fat M+F (g) 4322.6±267.1 3050±300.9 4601.1±402.9 0.002 RA vs. HC p=NS
AS vs. HC p=0.0003
Gynoid fat M (g) 3828.8±589.1 2877.9± 314.9 4337±663.4 NS
Gynoid fat F (g) 4608.4±239.8 4656.3±334.9 4940.7±355.3 NS
Visceral fat M+F (g) 1286.8±210.2 8061±123.1 770.6±92.9 0.03 RA vs. HC p=0.01
AS vs. HC p=NS
Visceral fat M (g) 1746.9±482.9 857.7±132.6 959.4±135.1 NS
Visceral fat F (g) 1005.7±145.3 324±78.6 527.8±103.2 0.01 RA vs. HC p=0.01
reaching the significance level (Kruskal–Wallis test p= 0.055).
Conversely, gynoid fat was found to be significantly different
(Kruskal–Wallis test p= 0.002), and this difference was related
to lower levels in the AS group compared to HC (Mann–Whitney
test p= 0.0003). However, this difference was not confirmed when
men and women were analyzed separately. Finally, the amount of
visceral fat was found to be significantly different between the
three groups (Kruskal–Wallis test p= 0.03), a difference that was
observed only in the RA group (Mann–Whitney test RA vs. HC
p= 0.01) (Figure 1), and especially in women (Kruskal–Wallis test
in women: p= 0.01 and Mann–Whitney test in women RA vs. HC
p= 0.01).
Relationships between adipose tissue measurements or serum
adipokine levels and disease activity
No relationship was observed between leptin or leptin/fat mass
and markers of disease activity in patients with AS (in the whole
group or in male AS patients) (all p> 0.05). In patients with
RA, HMW/total adiponectin correlated with the DAS28 score
(r =−0.42, p= 0.02). In AS, total fat mass was correlated with
CRP levels (r =−0.37, p= 0.04), while lean mass correlated
with ESR (r =−0.38, p= 0.04) and weakly with IL-6 (r =−0.35,
p= 0.053) and BASDAI (r =−0.32, p= 0.08). Finally, adiposity
correlated with DAS28 in patients with RA (r =−0.43, p= 0.02),
while there was a tendency toward a correlation with CRP in AS
(r =−0.37, p= 0.07). There was no relationship between visceral
fat mass and indices of disease activity in patients with RA.
FIGURE 1 | Measurement of fat in the android and visceral regions in
patients with rheumatoid arthritis (N =30), ankylosing spondylitis
(N =31), and healthy controls (N =51). Results are given for men and
women. Comparisons were performed using the Kruskal–Wallis test;
**p≤0.01.
DISCUSSION
In this study including patients and HC with comparable BMI,
abnormal adipose tissue distribution was found in both RA and
AS. Patients with RA were characterized by an accumulation of fat
in the visceral region, especially in women, while for AS, fat mass
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was decreased, albeit without reaching statistical significance. In
parallel, there was a tendency toward increased lean mass in AS
patients. These results were correlated with disease activity, par-
ticularly adiposity in patients with RA or lean mass in patients
with AS.
There are a limited number of studies evaluating body com-
position in RA and this study is the first to specifically measure
the intra-abdominal/visceral region. Body composition has been
assessed in RA in patients with early or longstanding disease. In
early RA, a low lean mass was found in both men and women,
while only women had higher BMI, body fat mass, and fat mass
ratio (defined by the fat localized to the trunk divided by the
sum of the fat of the arms and legs) than the control popula-
tion (23). In patients with later disease, similar changes involving
fat and lean masses were observed, but affecting both men and
women (24). Fat distribution was altered with a clear shift to the
abdominal region in most of these studies (23–25). The paral-
lel loss of skeletal muscle and increase in fat makes it possible to
define body composition phenotypes such as sarcopenia, overfat,
and sarcopenic obesity (18). These different studies found that
such phenotypes were highly represented in RA with long disease
duration (24). In an Asian population from Vietnam, women with
early disease also had a high proportion of similar unhealthy body
composition phenotypes (26). In all these studies, body compo-
sition was assessed using DXA, which evaluated total body and
regional fat mass. They showed abnormal values for all measures
of adiposity, including truncal fat. This is a well known factor
for cardiovascular disease in non RA patients, and it is assumed
that it could have similar effects in RA (9). However, these studies
of body composition in RA cannot specify whether the fat was
localized subcutaneously or in the abdominal cavity. Indeed, an
excess of intra-abdominal fat or visceral adipose tissue has been
reported to be detrimental and associated with metabolic abnor-
malities including hyperinsulinemia, insulin resistance, glucose
intolerance, lipid abnormalities, inflammation, and endothelial
dysfunction (6, 13). Moreover, excess visceral adipose tissue has
been significantly correlated with various cardiometabolic abnor-
malities, independently of the amount of subcutaneous fat (9).
In our female patients with RA, we found an excess of visceral
adipose tissue and this may influence their cardiovascular risk.
A number of previous studies in RA have shown an association
between abnormal body composition and CRP, but also HAQ and
rheumatoid factor positivity (23, 24). Truncal fat in patients with
RA was selectively associated with CRP levels (27). However, this
association between markers of disease activity or severity and
fat mass has not always been confirmed (25). We were unable
to demonstrate such an association, especially between visceral
fat and CRP and/or IL-6 levels. However, DAS28 correlated with
adiposity, a finding similar to the observations in Vietnamese
women with RA (26). These results suggest the influence of dis-
ease activity and thus persistent inflammation on fat deposition
and distribution. Lean mass was preserved in our patients with
RA, contrary to previous works (23, 24). The decrease in skele-
tal muscle contributes to sarcopenia, a well established feature of
RA that could induce weakness, fatigue, disability, and increased
risk of falls (23). Our population of RA patients did not have this
body composition phenotype. Despite high disease activity and
a mean disease duration of 11 years, the HAQ score was not very
high in our patients. This could explain maintained physical activ-
ity and muscle function, and thus the absence of muscle loss. In
addition, we previously reported that patients with RA had high
growth hormone levels, and such anabolic factors may contribute
to muscle mass (28). Conversely, the majority of our patients had
CTC at a low dosage, a treatment that can induce loss of skeletal
muscles (29).
Our group of patients with AS were characterized by a decrease
in total fat mass that almost reached statistical significance, as well
as a significant decrease in adiposity, while total lean mass tended
to be increased. Results were less salient when this patient group
was divided according to gender, and thus, results for adiposity
may reflect the low proportion of female AS patients. In addi-
tion, visceral fat was comparable between AS and HC. Previous
works evaluating body composition in AS using DXA are lim-
ited. A previous study by our group did not observe differences
in lean and fat masses between patients and HC (3), and simi-
lar results have also been reported by others (30). However, these
studies examined total body composition measurements (total fat
and lean mass) and not the regional distribution of fat mass.
Indeed, in patients with very long disease duration, appendicu-
lar lean mass was diminished compared to age- and sex-matched
controls (2). This loss of muscle mass was significantly associated
with reduced upper and lower body strength, providing evidence
for clinical features of cachexia. By contrast, total fat and truncal
fat were not modified in this AS population. Body composition
was also assessed by methods other than DXA including bioelec-
trical impedance analysis (31). Body fat was found to be reduced
using this method, while air-displacement plethysmography did
not show any difference between AS and controls for the percent-
age of fat mass or fat free mass (32). The disparities in these results
may be explained by the patient characteristics, the disease severity
and duration, the treatment given and the methods used for assess-
ing body composition (DXA vs. other methods). However, DXA is
considered as the reference method for measurements of body
composition, compared to bioelectrical impedance assessment.
There was a tendency toward low fat mass and a high lean mass
in our patients with AS. This may be related to preserved physi-
cal activity, as suggested by a low mean BASFI score. In addition,
we observed an inverse relationship between measures of disease
activity (ESR, IL-6, and BASDAI) and lean mass. Conversely, the
loss of adipose tissue in our AS group could be explained by the
systemic inflammation, as suggested by the relationship between
fat mass and CRP levels. However, we did not specifically evaluate
appendicular (arm and leg) lean mass, and thus, selective muscle
loss cannot be ruled out in our AS population.
Abnormal values for certain circulating adipokines were found
in our study. Resistin and ghrelin showed comparable levels
between the three groups, even when men and women were ana-
lyzed separately, whereas leptin was significantly decreased in male
AS patients, and total adiponectin and HMW/total adiponectin
ratio were increased in patients with RA. Circulating adipokines
have been extensively studied in RA (33) and to a lesser extent
in AS (31, 34, 35). The interest of adipokines in inflammatory
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rheumatic diseases comes from the discovery of the biological
properties of these proteins, and especially, their interplay with
the immune system. Leptin has a globally pro-inflammatory effect
by inducing a Th1 response (10, 12). In RA, serum leptin levels
were found to be higher than in controls in most previous analy-
ses, but some studies found no differences [for review, see Ref.
(12)]. These discrepancies may be explained by the lack of adjust-
ment for BMI or the absence of analysis by gender. In our study,
we adjusted leptin for the total fat mass (and not the BMI), a cor-
rection that seems more relevant since leptin is a direct surrogate
marker of the amount of adipose tissue (10). Leptin has previ-
ously been evaluated in AS by our group and we found similar
results as compared to the present study (34). Both decreased and
increased levels of leptin in AS have been reported by other studies,
without any clear explanation for these contradictory results (31).
Despite the lack of association between leptin and disease activity,
we can hypothesize that decreased leptin levels in AS may favorably
influence the inflammatory response in AS (34). Total adiponectin
was increased in our RA group with a weak parallel change in
HMW adiponectin. Again, adiponectin has previously been eval-
uated in RA showing increased levels in general (33). Adiponectin
has been determined to be a factor associated with disease severity
or joint destruction: two studies reported that baseline adiponectin
is related to radiographic joint damage (36, 37), while the oppo-
site was found in a third study (38). One explanation for these
discrepancies is that adiponectin exists in different isoforms, with
the HMW form driving inflammation (14, 16). Studies conducted
to date in RA measured exclusively total adiponectin, and not its
isoforms. Our results suggest that when studying adiponectin in an
inflammatory condition, the assessment of its different isoforms
is required.
Serum ghrelin was comparable between the three groups in our
study. Ghrelin is a gastric peptide involved in energetic balance:
contrary to leptin, it stimulates appetite and decreases fat utiliza-
tion. We previously observed elevated ghrelin levels in AS, and this
result was thought to mitigate inflammation in these patients (34).
Indeed, ghrelin is able to inhibit the release of pro-inflammatory
cytokines, such as IL-1, IL-6, and TNFα. We did not confirm these
previous results in this study, and this may be related to the patient
characteristics.
Since adipose tissue is at the crossroads of energy homeosta-
sis, inflammation, and atherosclerosis, the metabolic profile of
our patients was also evaluated. We used HOMA-IR to deter-
mine insulin sensitivity and this parameter was not affected in
any group. Resistin is described as an adipokine related to insulin
resistance in animal models, although the evidence of this effect
in humans is less clear (13). However, our patients had resistin
levels comparable to those of HC. Conversely, total adiponectin
(with, in parallel, HMW adiponectin) was increased in the RA
group. Besides its effect on inflammation, adiponectin is known
as a protective metabolic factor. Indeed, adiponectin promotes
insulin sensitivity, and thus, is decreased in patients with obe-
sity, diabetes, or metabolic syndrome. Adiponectin is considered
to be a protective cardiovascular factor, and it has been estab-
lished that it can predict future cardiovascular events in patients
with coronary heart disease (13). When considering the normal
results of HOMA-IR and resistin levels together with the nor-
mal atherogenic index, as well as the increased adiponectin levels,
the cardiometabolic profile of our patients with RA thus seems
favorable.
Finally, this study has strengths and limitations. We evaluated
the amount and distribution of adipose tissue, focusing for the
first time on the visceral region. These measurements were per-
formed together with the assessment of their derived products and
specific cardiometabolic indexes. High molecular adiponectin was
also evaluated in this study. However, a low proportion of female
AS patients was evaluated and this could influence our results.
For this reason, we carefully analyzed our patients according to
gender. A clear sexual dimorphism is established for serum leptin,
and to a lesser extent, for adiponectin, with women having higher
serum leptin and adiponectin that men. For resistin, it is thought
that women also have higher serum levels (39) whereas there is no
influence of sex on serum ghrelin. In addition, our RA patients
were older compared to AS and HC subjects. Aging could influ-
ence serum adipokines: in fact, it has been demonstrated that the
levels of adiponectin (both in male and female subjects) and leptin
(in males) were significantly higher in older subjects compared to
their younger counterparts (40), but these results were observed
in a population aged between 70 and 80 years. Our RA patients
and HC had a limited age difference (around 10 years) and we
did not include patients aged over 73 years. Presumably, the age
difference between RA and HC did not influence our adipokine
results.
CONCLUSION
We conclude that body composition is altered in both RA and
AS, but with different soft tissue impact. Patients with RA had
increased measurements of adiposity and visceral fat deposition,
especially in women, while in AS, fat mass was decreased and lean
mass increased. There was no accumulation of visceral fat in AS.
These differences in body composition certainly reflect distinct
pathophysiological mechanisms. Patients with RA and AS have
also distinct circulating adipokine profiles. Increased fat mass in
the visceral region may potentially worsen the cardiovascular risk
in women with RA, but the favorable cardiometabolic profile in
these patients may attenuate the deleterious effect of this fat depo-
sition. However, longitudinal studies are warranted to evaluate the
real impact of visceral fat accumulation in RA on cardiovascular
risk, together with the levels of circulating adipokines, such as
adiponectin.
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